Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2025 07h00 HE | Source: AlphaTON Capital

AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

Dover, DE and Sydney, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado...
07 nov. 2025 07h00 HE | Source: AlphaTON Capital

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

Dover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics...
06 janv. 2025 05h00 HE | Source: Portage Biotech Inc.

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company